Recurrence of leukemia is a major problem after autologous stem cell transplantation. One potential means of reducing this risk is to purge the autologous transplant in vitro by hyperthermia. We have demonstrated that after a hyperthermic treatment of 120 min at 43؇C, the leukemic progenitor cells (CFU-AML) are decreased by 5-log but the normal hematopoietic committed progenitor cells (CFU-GM, BFU-E and CFU-E) are reduced by only 1-log. Moreover, the hyperthermic sensitivity coincides with the stem cell hierarchy, ie CFU-GM are less heat sensitive than BFU-E, while CFU-E are the most sensitive. The impact of pretreatment with the tetrapeptide AcSDKP (Goralatide) on the proliferative activity and heat sensitivity of the normal and leukemic progenitor cells was determined. An incubation of 21 h at 37؇C with 10 ؊9 M Goralatide reduces the number of normal hematopoietic progenitor cells in S-phase and concomitantly decreases their hyperthermic sensitivity. This effect implies that the proliferative activity is the major determinant for the detected differences in hyperthermic sensitivity of the subsets in the normal hematopoietic stem cell compartment. In contrast, the cell cycle progression of leukemic progenitor cells is not affected and hence these cells are not protected from hyperthermia-induced cell killing after preincubation with Goralatide. Thus, the treatment with Goralatide increases the therapeutic window of hyperthermia and increases the potential value of this physical purging technique.
to relapse [3] [4] [5] [6] strengthens the use of purging modalities in clinical settings. Hyperthermia can be considered as a potent in vitro purging agent as demonstrated in murine and human normal bone marrow and leukemic cell suspensions. [7] [8] [9] [10] In the murine system, it was shown that the differences in heat sensitivity of the normal subsets in the hematopoietic stem cell compartment are related to the differences in proliferative activity. [11] [12] [13] [14] The primitive hematopoietic stem cell with long-term repopulating ability, which has a quiescent cell cycle status in normal bone marrow, is less sensitive to hyperthermic treatments than the active proliferating committed progenitor subsets. In addition, it could be shown that an increase in the proliferative activity of a subset, increases the hyperthermic cell killing effect on that particular subset. 11, 2 Hematopoietic cell proliferation is modulated by a series of positive and negative regulators. 15 The tetrapeptide AcSDKP (Goralatide) belongs to the family of negative regulators. 16 This peptide inhibits entry into the S-phase of the cell cycle. [17] [18] [19] Such proliferative arrest might decrease the hyperthermic sensitivity of human hematopoietic cells, an effect already demonstrated in murine bone marrow. 9, 10 In contrast, leukemic cells have abnormal cell cycle regulation and may therefore be less sensitive to inhibition by a negative regulator such as Goralatide. We therefore determined the effect of proliferative activity on the heat sensitivity of the committed granulocyte-macrophage progenitors (CFU-GM) and the late and early erythroid progenitor cells (BFU-E and CFU-E) in normal and remission human bone marrow. We also compared the effect of Goralatide on the cell cycle activity of normal and malignant hematopoietic progenitors and ascertained its effect on the hyperthermic sensitivity of these cells.
Materials and methods

Hematopoietic cells
Bone marrow cells from patients in complete remission and from BMT donors were collected. Informed consent was obtained for the use of cells for research purposes. Mononuclear cells were separated on Ficoll-Paque Plus (Pharmacia Biotech, Uppsala, Sweden). The cells were resuspended in RPMI-1640 medium (GIBCO BRL, Grand Island, NY, USA) by dispersion through a 21-gauge needle. Nucleated cells were counted in a hemocytometer.
AML cells
Bone marrow cells from five patients with AML classified according to the FAB Committee criteria were obtained from the St Jude Children's Research Hospital bone marrow cell bank. Four patients were classified as M2 and one as M4. Cells were thawed rapidly at 37°C, washed twice with RPMI-1640 medium and counted. Viability was always Ͼ95%. 
Goralatide treatment
Proliferative activity
The proliferative activity of the leukemic cells and hematopoietic progenitor cells was determined by the hydroxyurea-kill assay. 13 In brief, hydroxyurea (200 g/ml) was added to aliquots of cell suspensions Ϯ Goralatide after 0 and 20 h, respectively, and incubated for another 60 min at 37°C. The cells were then washed and plated out for the colony-forming assays.
Hyperthermic treatments
The cell suspensions were placed in culture tubes at a concentration of 2-3 ϫ 10 6 /ml in RPMI-1640 medium with or without 10% FCS. The hyperthermic treatments were performed at 43 ± 0.1°C up to 120 min and interrupted by chilling. Cells were diluted to the appropriate concentration and immediately used for the colony-forming assays.
Colony-forming assays
Bone marrow cells from donors or remission bone marrow and AML cells were plated out in duplicate in methylcellulose medium (StemCell Technologies, Vancouver, Canada) at concentrations varying from 5 ϫ 10 4 to 5 ϫ 10 6 nucleated cells/ml. In this culture system colony growth is stimulated by the addition of agar leukocyte-conditioned medium and erythropoietin. Cultures were grown in 35-mm polystyrene culture dishes (Falcon; Becton-Dickinson) at 37°C in a 5% CO 2 humidified atmosphere. In normal/ remission bone marrow, the colonies (Ͼ20 cells) containing hemoglobinized cells were scored as CFU-E at day 8 of culture. After 14 days of culture, colonies (Ͼ50 cells) containing hemoglobinized cells were scored as BFU-E and those without any sign of hemoglobin as CFU-GM. In leukemic bone marrow, the blast colonies (Ͼ20 cells) were scored after 14 days. Figure 1 shows the effect of hyperthermic treatment at 43°C on normal hematopoiesis from donor bone marrow or remission bone marrow and from leukemic progenitor cells. CFU-GM are less sensitive to heat than the erythroid progenitors BFU-E and CFU-E. The heat-induced cell kill of the leukemic progenitor CFU-AML is about 4-log after 90 min at 43°C while normal subsets are reduced by less than half. With the clonogenic assay the detection limit is a 4-log reduction in cell viability. By extrapolation, however, an increase to 5-log leukemic cell depletion after 120 min at 43°C is feasible, at which point the normal subsets are killed by approximately 1-log. To investigate a possible protective effect of serum, the heat treatment was also performed without serum. As can be seen in Figure 2 , a moderate protection of the normal subsets is observed in the presence of serum. However, the heat-induced cell killing of leukemic progenitor cells is not reduced. Figure 3 shows the effect of Goralatide on the proliferative activity of progenitor cells in normal or remission bone marrow and bone marrow from leukemic patients at diagnosis. In the controls, the erythroid progenitor cells are actively proliferating since respectively 38 and 30% of the Minutes at 43°C CFU-E and BFU-E, are in S-phase. CFU-GM showed the lowest proliferative activity, with only 10% in S-phase. No significant differences in proliferative activity between progenitors from normal or remission bone marrow could be detected. Hence, from here on the term 'normal' will be used and includes both sources of hematopoietic progenitor cells. A 21-h incubation with 10 Ϫ9 m Goralatide reduced the proliferative activity of all three progenitor subsets, so that Ͻ7% were in S-phase. In contrast to the CFU-GM, the leukemic CFU-AML show an extremely high proliferative activity (Ͼ60% S-phase cells) but appear to be insensitive to Goralatide. Table 1 shows the effect of the incubation Ϯ Goralatide on the total number of progenitor cells. In normal bone marrow almost all nucleated cells are recovered. Although Goralatide reduces the proliferative activity of normal progenitors, it has no effect on viability except the CFU-E. This subset decreases to Ӎ50% of the initial number. The numbers of nucleated cells and progenitors in leukemic bone marrow are slightly decreased after incubation. (1) 1 (1) 30 (3) 1 (5) 38 (0.3)
Results
Hyperthermic sensitivity of normal and AML progenitors
Effect of Goralatide on the proliferative activity of normal and AML progenitors
(3)
62 (8) 71 (4) Figure 3 Effect of Goralatide on the proliferative activity of normal and leukemic progenitors. Cells were incubated for 21 h at 37°C in the absence (dashed bars) or presence (black bars) of 10 Ϫ9 m Goralatide. Data are obtained normal/remission bone marrow and leukemic bone marrow samples of three different donors or patients. Calculation of the %S-phase was performed as followed: 100 − (CFU present after hydroxyurea inc/CFU present without hydroxyurea inc × 100). The average percentage of cells in S-phase is also shown in the Table. The numbers in parenthesis represent s.e.m.
Table 1
Recovery of the number of nucleated cells and progenitor subsets in normal and AML bone marrow after an incubation Ϯ Goralatide Bone marrow cells were incubated for 21 h at 37°C Ϯ 10 Ϫ9 m Goralatide. − = without Goralatide; + = with Goralatide Data are expressed as % (Ϯ s.e.m.) of the initial number of nucleated cells or progenitor subsets.
Nucl cells CFU-GM BFU-E CFU-E CFU-AML
Impact of Goralatide on the heat sensitivity of normal and AML progenitors
The contrasting effect of Goralatide on the proliferative activity of normal vs malignant progenitor cells has a major impact on the effects of hyperthermia. Figure 4 shows the overall effect of the Goralatide pretreatment on the heat sensitivity of the normal and leukemic progenitors. A marked protective effect was seen for all normal subsets due to the decrease in proliferative activity. For the leukemic progenitor cells, the hyperthermic sensitivity remains unchanged after Goralatide pretreatment. Hence, Goralatide effectively increases the therapeutic index of hyperthermic purging.
Discussion
In this article, we describe a means by which the safety and efficacy of hyperthermic purging may be greatly increased by taking advantage of the differing biological response of normal and malignant progenitor cells to Goralatide, a tetrapeptide that modulates the cell cycle. Although no clinical trials have been designed to document the minimal number of progenitor cells needed for shortterm engraftment, evidence exists that the CFU-GM content can be decreased to 1-5% of the initial value without slowing hematological recovery. 20, 21 Our data show that a hyperthermic treatment of 120 min at 43°C results in 1-log decrease in CFU-GM survival (Figure 1) . We realize that knowledge about the hyperthermic sensitivity of the primitive hematopoietic stem cell is indispensable before establishing a hyperthermic purging protocol. Our murine studies, 13, 14 showed that differences in the proliferative activity between the subsets is the main determinant of the observed differences in hyperthermic sensitivity, ie subsets with a quiescent cell cycle state are less sensitive to heat treatment than actively proliferating subsets. Based on these data and those presented in this study, we might conclude that the human primitive hematopoietic stem cell will be less likely to be in cell cycle and therefore will be less sensitive to heat than the CFU-GM. An efficient purging therapy must not only spare sufficient normal hematopoietic cells to allow engraftment, but must also be highly toxic to leukemic cells. Our data already show a 4-log reduction in a tumor burden after 90 min at 43°C. In combination with the reduction of normal progenitor cells by less than half, this indicates the feasibility of hyperthermia as a purging modality. Our data on the heat sensitivity of the normal human hematopoietic progenitors are consistent with those reported by others. [22] [23] [24] [25] Moriyama et al 25 showed that in human bone marrow the multi-lineage progenitor cell is less heat-sensitive than the lineage-restricted progenitor cells. However, in that study no attempts were made to correlate the heat sensitivity with the proliferative activity of the subsets. In the current study no protective effect of serum on the heat-induced cell kill of the leukemic progenitor could be demonstrated (Figure 2) as was suggested by others. 22 Although these results offer encouragement for the use of hyperthermia, it would be highly desirable to obtain a further decrease in the hyperthermic sensitivity of the normal progenitor cells which in turn would allow an increase in the hyperthermic dose and augment the elimination of leukemic cells. Decreasing the proliferative activity is a logical approach to reducing the heat-induced killing of progenitor cells, but will only result in benefit if the antileukemic effect is maintained. Goralatide has proven to be a selective protector of normal murine progenitor subsets. 9, 10, 18, 19 In this study we could confirm the selective inhibitory effect of Goralatide on human progenitor cells (Figure 3) . The number of S-phase cells in all three normal subset compartments decreased to below 7% after a 21-h incubation with 10 Ϫ9 M Goralatide at 37°C. Concomitantly the hyperthermic sensitivity of all subsets decreased to comparable levels ( Figure 4) . The reason that the heat sensitivity of leukemic progenitor cells is not decreased by Goralatide appears to be due to the insensitivity of these cells to the cell cycle inhibitory action of Goralatide, since the number of S-phase cells of the leukemic cells before and after the Goralatide treatment remains Ͼ60% ( Figure  3) . Hence, the overall effect of the Goralatide pretreatment is an increase in the therapeutic ratio of the hyperthermic purging modality (Figure 4) . The mechanism of inhibition by Goralatide is as yet unknown. It might act through the inhibition of cyclin D 1 synthesis as is described for TGF-␤1-modulated inhibition of cell cycle progression. 26 These D-type cyclins are essential for the cell cycle transition from G 1 to S-phase. In malignant cells these D-type cyclins may be abundantly present and an inhibition of cyclin D 1 synthesis might not affect the cell cycle status of leukemic cells. By contrast, in normal progenitor subsets this inhibition leads to cyclin D 1 levels below the threshold value needed for cell cycle progression.
Taken together, we can conclude that the differences in heat sensitivity between the normal progenitor and its leukemic counterpart makes hyperthermia an effective purging modality. The hyperthermic sensitivity of the progenitor subsets in human bone marrow is related to the proliferative activity. The negative regulator of hematopoiesis Goralatide decreases the proliferative activity of the progenitor subsets and hence their hyperthermic sensitivity, but has no activity on leukemic progenitor cells. As a consequence, the therapeutic ratio of this purging modality can be increased by pretreatment with Goralatide.
